German corporation Bayer will rely on commercialization of its new pharmaceutical products to bolster its profits in the year ahead.
A recent report by the corporate giant trumpets its sales in the past year, stating they rose by 4.1 percent in 2011 to $48.2 million. The report specifically mentions Bayer’s HeathCare subgroup, responsible for pharmaceutical products, as contributing to the profitability.
“One of our strengths continues to be our well-stocked development pipeline in pharmaceuticals,” Bayer CEO Dr. Marijn Dekkers said. Several times, ...
continue reading...